Neuren Pharmaceuticals’ hypothetical takeover value is estimated at up to $15 billion…
A $15 billion valuation assumessuccessful progression through Phase 3, FDA approvals for multiple indications, and a strategic buyer (e.g., Pfizer, Novartis, Gilead) willing to pay a premium for Neuren’s pipeline, similar to high-value rare disease acquisitions in the biotech sector...
Reata’s takeover occurred in 2023, while Neuren’s potential takeover would be in 2025
Steed1, this doesn’t make sense.
Firstly, a takeover valuation of $15bn (AU? US?) is proposed for Neuren IF NNZ-2591 successfully passes Phase 3 and is subsequently approved by the FDA in multiple indications (with those indications previously stated to be Phelan-McDermid syndrome, Angelman syndrome, Pitt-Hopkins syndrome and Prader-Willi syndrome).
Then it is proposed that this takeover would occur in 2025.
Even assuming smooth and successful progression from this point, the first FDA approval for NNZ-2591 in Phelan McDermid won’t happen before late 2028, Pitt Hopkins and Angelman before 2029 and Prader-Will at some time later.
NEU Price at posting:
$14.04 Sentiment: Hold Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)